Search

Your search keyword '"Graham, Janet"' showing total 610 results

Search Constraints

Start Over You searched for: Author "Graham, Janet" Remove constraint Author: "Graham, Janet" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
610 results on '"Graham, Janet"'

Search Results

3. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors

5. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

6. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

9. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

11. BAO NINH: Ha Noi at Midnight

13. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

14. Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.

15. NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.

19. Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors

20. Assisted peritoneal dialysis: Position paper for the ISPD

23. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

28. PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.

29. The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer

30. Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

31. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

33. Speaking Math: Using Chat in the Multicultural Math Classroom

34. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial

35. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

36. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

37. Teratogenicity of zonisamide and other little-used antiseizure medications.

39. DNA methylation changes associated with acquired platinum resistance in ovarian cancer

40. An exploration of African-Caribbean boys’ underachievement and their stories of schooling

41. Increasing Relevancy in a Speaking Course for Graduate Students.

43. Changing Fossilized Speech: What Does It Take?

44. Is Contextualised Admission the Answer to the Access Challenge?

45. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer

46. Supplementary Methods 4 from Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival

47. Supplementary Methods 6 from Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival

48. Supplementary Methods 1 from Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival

49. Supplementary Methods 5 from Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival

50. Supplementary Methods 3 from Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival

Catalog

Books, media, physical & digital resources